JNJ (Johnson & Johnson) Long-Term Debt: $37,527 Mil (As of Mar. 2026)


JNJ Johnson & Johnson JNJ
81 GF Score
Price $256.98
GF Value $191.09
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Long-Term Debt?

Johnson & Johnson JNJ -0.82% 81 Long-Term Debt is $37,527 Mil as of Mar. 2026. GuruFocus rates JNJ with a GF Score™ of 81/100 and a GF Value™ of $191.09 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Johnson & Johnson's Long-Term Debt for the quarter that ended in Mar. 2026 was $37,527 Mil.

Johnson & Johnson's quarterly Long-Term Debt increased from Sep. 2025 ($39,408 Mil) to Dec. 2025 ($39,438 Mil) but then declined from Dec. 2025 ($39,438 Mil) to Mar. 2026 ($37,527 Mil).

Johnson & Johnson's annual Long-Term Debt increased from Dec. 2023 ($25,881 Mil) to Dec. 2024 ($30,651 Mil) and increased from Dec. 2024 ($30,651 Mil) to Dec. 2025 ($39,438 Mil).

Johnson & Johnson  (NYSE:JNJ) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Johnson & Johnson Long-Term Debt Related Terms

Johnson & Johnson Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Johnson & Johnson's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Johnson & Johnson Long-Term Debt Chart

Johnson & Johnson Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29,985.00 26,886.00 25,881.00 30,651.00 39,438.00

Johnson & Johnson Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38,355.00 39,235.00 39,408.00 39,438.00 37,527.00
JNJ
81GF Score
Johnson & Johnson JNJ
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $37,527 Mil mean?
Johnson & Johnson (JNJ) has a Long-Term Debt of $37,527 Mil as of Mar. 2026.
Is Johnson & Johnson's Long-Term Debt too high?
Johnson & Johnson's current Long-Term Debt is $37,527 Mil. Overall, Johnson & Johnson has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Johnson & Johnson's Long-Term Debt compare to ABBV and MRK?
Johnson & Johnson's Long-Term Debt of $37,527 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Johnson & Johnson's current Long-Term Debt is $37,527 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Johnson & Johnson stock overvalued right now?
Based on GuruFocus' analysis, Johnson & Johnson (JNJ) is currently considered Significantly Overvalued. The stock's GF Value™ is $191.09, compared to a current price of $256.98 — trading 34.5% above its estimated fair value. The current Long-Term Debt is $37,527 Mil. Johnson & Johnson's overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Johnson & Johnson (JNJ), the current Long-Term Debt is $37,527 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Johnson & Johnson (JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of $256.98 is trading 34.5% above its estimated GF Value™ of $191.09. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for JNJ:

  • Long-Term Debt: $37,527 Mil
  • GF Value™: $191.09 vs. price of $256.98 (34.5% above fair value)
  • GF Score™: 81/100 with 7 warning signs

No single metric tells the full story. See the JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
81GF Score

Get the complete analysis for JNJ

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$256.98
Price
$191.09
GF Value